


1645
#6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DEX-0279
Inventors: Salceda et al.
Serial No.: 10/001,885
Filing Date: November 20, 2001
Examiner: Not Yet Assigned
Group Art Unit: 1645
Title: Compositions and Methods Relating to
Ovary Specific Genes and Proteins

I, Kathleen A. Tyrrell, Registration No. 38,350, certify that this correspondence is being depositing with the U.S. Postal Service as First Class mail in an envelope addressed to the U.S. Patent and Trademark Office, Box 2327, Arlington, VA 22202

On this date: February 13, 2003


Kathleen A. Tyrrell, Registration No. 38,350

U.S. Patent and Trademark Office
Box 2327
Arlington, VA 22202

Sir:

RECEIVED

FEB 24 2003

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into

the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

- () In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
 - () Certification in Accordance with §1.97(e) is set forth below; or
 - () The fee of \$180.00 as set forth in §1.17(p) is attached.
- () In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I)(1).
- (XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.
- () In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously


submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.


Respectfully submitted,


Kathleen A. Tyrrell
Registration No. 38,350

Date: February 13, 2003

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515



Sheet 01 of 01

Form PTO-1449 Modified

Docket No.
DEX-0279Serial No.
10/001,885

RECEIVED

List of Patents and Publications
Cited by Applicant
(Use several sheets if necessary)

FEB 24 2003

TECH CENTER 1600/290

U.S. Department of Commerce


Applicant
Salceda et al.Filing Date
November 20, 2001Group
1645

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AA	Aaltonen et al., "Human Growth Differentiation Factor 9 (GDF-9) and Its Novel Homolog GDF-9B Are Expressed in Oocytes during Early Folliculogenesis", Journal of Clinical Endocrinology and Metabolism 1999 84(8):2744-2750
AB	Haile et al., "Activation of Transcription in Vitro by the BRCA1 Carboxyl-terminal Domain", J. Biol. Chem. 1999 274(4):2113-2117 XP-002225103
AC	Hinshelwood et al., "The 5'-Flanking Region of the Ovarian Promoter of the Bovine CYP19 Gene Contains a Deletion in a Cyclic Adenosine 3',5'-Monophosphate-Like Responsive Sequence", Endocrinology 1997 138(9):3704-3710
AD	Database EMBL, EBI; 8 October 1999 DOE JOINT GENOME INSTITUTE: "Homo sapiens chromosome 19 clone CTC-21504, complete sequence", Database accession no. AC011442 XP-
AE	Database EMBL, EBI; 12 June 1999 Birren et al., "Homo sapiens chromosome 17 clone RP5-962P8 map 17", Database accession no. AC007775 XP002225106

EXAMINER

DATE CONSIDERED



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DEX-0279
Inventors: Salceda et al.
Serial No.: 10/001,885
Filing Date: November 20, 2001
Examiner: Not Yet Assigned
Group Art Unit: 1645

RECEIVED

FEB 24 2003

TECH CENTER 1600/2900

Title: Compositions and Methods Relating to
Ovary Specific Genes and Proteins

I, **Kathleen A. Tyrrell**, Registration No. **38,350**, certify that this correspondence is being depositing with the U.S. Postal Service as First Class mail in an envelope addressed to the U.S. Patent and Trademark Office, Box 2327, Arlington, VA 22202

On this date: February 13, 2003


Kathleen A. Tyrrell, Registration No. 38,350

U.S. Patent and Trademark Office
Box 2327
Arlington, VA 22202

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into

the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

() In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

() Certification in Accordance with §1.97(e) is set forth below; or

() The fee of \$180.00 as set forth in §1.17(p) is attached.

() In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I)(1).

(XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

() In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously


submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,


Kathleen A. Tyrrell
Registration No. 38,350

Date: **February 13, 2003**

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515



Sheet 01 of 01

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce	Docket No. DEX-0279	Serial No. 10/001,885
	Applicant Salceda et al.	
	Filing Date November 20, 2001	Group 1645

RECEIVED

FEB 24 2003

TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AA	Aaltonen et al., "Human Growth Differentiation Factor 9 (GDF-9) and Its Novel Homolog GDF-9B Are Expressed in Oocytes during Early Folliculogenesis", Journal of Clinical Endocrinology and Metabolism 1999 84(8):2744-2750
AB	Haile et al., "Activation of Transcription <i>in Vitro</i> by the BRCA1 Carboxyl-terminal Domain", J. Biol. Chem. 1999 274(4):2113-2117 XP-002225103
AC	Hinshelwood et al., "The 5'-Flanking Region of the Ovarian Promoter of the Bovine CYP19 Gene Contains a Deletion in a Cyclic Adenosine 3',5'-Monophosphate-Like Responsive Sequence", Endocrinology 1997 138(9):3704-3710
AD	Database EMBL, EBI; 8 October 1999 DOE JOINT GENOME INSTITUTE: "Homo sapiens chromosome 19 clone CTC-21504, complete sequence", Database accession no. AC011442 XP-
AE	Database EMBL, EBI; 12 June 1999 Birren et al., "Homo sapiens chromosome 17 clone RP5-962P8 map 17", Database accession no. AC007775 XP002225106

EXAMINER	DATE CONSIDERED
----------	-----------------